Free Trial
NASDAQ:TCRT

Alaunos Therapeutics Q4 2025 Earnings Report

Alaunos Therapeutics logo
$2.63 0.00 (0.00%)
As of 12:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alaunos Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alaunos Therapeutics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alaunos Therapeutics Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Alaunos Therapeutics' Q1 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Alaunos Therapeutics Earnings Headlines

The chokepoint supplier behind SpaceX's $1.75 trillion empire
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines. But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.tc pixel
See More Alaunos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email.

About Alaunos Therapeutics

Alaunos Therapeutics (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

View Alaunos Therapeutics Profile